Acrivon Therapeutics (ACRV) Selling, General & Administrative (2023 - 2026)
Acrivon Therapeutics' Selling, General & Administrative was $4.82 million in Q2 2026, down 25.4% from $6.47 million a year earlier but up 1.9% from the prior quarter.
Powered by 
Analysis
Acrivon Therapeutics (ACRV) Selling, General & Administrative (2023 - 2026) Analysis & Trends
On a trailing twelve-month basis, Acrivon Therapeutics' Selling, General & Administrative was $20.97 million through Jun 30, 2026, down 17.2% year-over-year; for FY2025, it was $24.12 million, down 4.3% from FY2024.
- Selling, General & Administrative shows a three-year compound annual growth rate of 40.4% (FY2022 to FY2025).
- In earlier years, Selling, General & Administrative was $25.21 million in FY2024 (+19.6%), $21.08 million in FY2023 (+142.1%) and $8.71 million in FY2022.
- Quarterly Selling, General & Administrative has moved between $4.64 million (Q1 2023) and $6.47 million (Q2 2025) over five years.
- Compared with a year earlier, Selling, General & Administrative has declined for four straight quarters, with an average decline of 5.8% over the last eight quarters.
- The best year-over-year quarter for Selling, General & Administrative over five years was Q1 2024 (growth of 33.7%); the worst was Q2 2026 (a decline of 25.4%).
- Per Business Quant data, ACRV's Selling, General & Administrative in the three quarters before Q2 2026 was $4.74 million (Q1 2026), $5.37 million (Q4 2025) and $6.04 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 3.43 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 6.43 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.63 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 2.90 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | -3.24 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | -5.65 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 1.75 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 1.92 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 3.41 Bn |
| 10 | Acrivon Therapeutics | 85.27 Mn | 85.27 Mn | - | 4.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.82 Mn |
| Mar 31, 2026 | 4.74 Mn |
| Dec 31, 2025 | 5.37 Mn |
| Sep 30, 2025 | 6.04 Mn |
| Jun 30, 2025 | 6.47 Mn |
| Mar 31, 2025 | 6.25 Mn |
| Dec 31, 2024 | 6.32 Mn |
| Sep 30, 2024 | 6.28 Mn |
| Jun 30, 2024 | 6.41 Mn |
| Mar 31, 2024 | 6.20 Mn |
| Dec 31, 2023 | 5.58 Mn |
| Sep 30, 2023 | 5.87 Mn |
| Jun 30, 2023 | 5.00 Mn |
| Mar 31, 2023 | 4.64 Mn |
API Access
Acrivon Therapeutics Selling, General & Administrative API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=selling-general-and-administrative&ticker=ACRV&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "selling-general-and-administrative", "ticker": "ACRV", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=selling-general-and-administrative&ticker=ACRV&period=max&api_key=YOUR_API_KEY");
const data = await res.json();